Sermorelin regulatory history: 1997 FDA approval to 2008 market withdrawal
Sermorelin received FDA approval in 1997 for paediatric GH-deficiency diagnostic use and was voluntarily withdrawn from the US market in 2008. The withdrawal is sometimes interpreted as a safety signal — it was not. The history is worth walking through because it clarifies how research peptides transition between prescription-medicine status and research-only categorisation.
1997 FDA approval
Sermorelin received FDA approval in 1997. The approved indication was diagnostic use in suspected paediatric pituitary-axis insufficiency — a single subcutaneous dose triggered a transient GH-release pulse that could be measured to assess pituitary GH-axis competence. Paediatric patients with adequate GH response to Sermorelin were generally classified as having normal pituitary axis function; absent or reduced response indicated suspected GH-deficiency requiring further evaluation.
The diagnostic protocol was clinically useful but also clinically narrow. The single-dose, transient-response design did not extend easily to other indications, and the molecule’s short half-life made chronic-administration uses challenging. The approved-indication market remained small throughout the approval period.
2008 voluntary withdrawal
In 2008, the original manufacturer (Serono, by then part of Merck Serono) voluntarily withdrew Sermorelin from the US market. The withdrawal letter cited commercial factors: declining demand for the Sermorelin diagnostic stimulation test (as newer GH-deficiency diagnostic protocols emerged), small approved-indication market, and the resulting commercial non-viability of continued manufacturing for a niche prescription product.
The FDA withdrawal-evaluation documentation did not identify any safety signal driving the decision. Eleven years of post-approval safety surveillance had not produced an adverse-event pattern requiring regulatory intervention. The market withdrawal was a commercial business decision, not a safety-driven recall.
Honest take: it’s common to find online sources implying Sermorelin was “withdrawn for safety reasons” or “banned.” Neither is accurate. The molecule was approved, the safety profile in approved use was clean, and the manufacturer withdrew it for commercial reasons. The current research-use-only status is a consequence of the commercial withdrawal, not a regulatory safety judgment.
Post-withdrawal status
Following the 2008 US market withdrawal, Sermorelin is no longer a prescription-medicine product in the US market. Research-grade Sermorelin remains available through laboratory suppliers for non-clinical research use. The molecule continues to be referenced in the broader GHRH-analogue research literature as the foundational comparator structure.
In some jurisdictions, Sermorelin is still available through licensed compounding pharmacies for off-label use under physician supervision. The compounding-pharmacy supply is regulated separately from the research-supply chain; the two should not be conflated. Wellness Labs supplies research-grade Sermorelin under the research-use-only framework; clinical-grade compounded Sermorelin under physician prescription is a separate regulatory channel.
UAE regulatory status
In the UAE, Sermorelin is not currently approved by the Ministry of Health as a clinical medicine. The molecule is available as research-grade material through laboratory suppliers operating under research-use-only frameworks. The UAE regulatory framework for research peptides is broadly similar to the US research-use-only categorisation that Sermorelin currently sits under.
Further reading
- Sermorelin parent overview.
- Sermorelin vs Tesamorelin.
- Sermorelin dosing in research protocols.
- Peptides legal status in the UAE.
Last reviewed 2 June 2026. Editorial inbox: info@uaewellnesslab.com.
Frequently asked questions
- When did Sermorelin receive FDA approval?
- 1997. The approval was for paediatric diagnostic use. The approved protocol was a single subcutaneous dose followed by serial GH-axis sampling to assess pituitary GH-axis competence — exactly the use case the short half-life enables.
- Why was Sermorelin withdrawn from the US market?
- Commercial reasons, not safety. The original manufacturer (Serono, by then part of Merck Serono) withdrew Sermorelin in 2008 because newer diagnostic protocols had largely replaced the Sermorelin stimulation test and the commercial volume no longer justified continued manufacturing for a niche prescription product. The 11 years of post-approval safety surveillance showed a clean safety profile.
- Is Sermorelin legal in the UAE?
- Sermorelin is not currently approved by the UAE Ministry of Health as a clinical medicine. Research-grade Sermorelin is available through laboratory suppliers operating under research-use-only frameworks. The UAE regulatory framework for research peptides is broadly similar to the US research-use-only categorisation that Sermorelin currently sits under.
- Was Sermorelin banned for safety reasons?
- No. The 2008 US market withdrawal is sometimes characterised as a safety-driven action in informal sources; this is not accurate. The withdrawal was a commercial business decision by the manufacturer. The FDA withdrawal-evaluation documentation did not identify a safety signal driving the decision. Post-approval safety surveillance through the approved years was clean.
- Can Sermorelin be obtained legally through a US compounding pharmacy?
- Some US compounding pharmacies still supply Sermorelin under physician prescription for off-label clinical use. This is a separate regulatory channel from the research-supply chain and from the original prescription-medicine status. The compounding-pharmacy supply operates under the broader compounding-pharmacy regulatory framework; the research-grade supply chain operates under the research-use-only framework.